SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-430967"
 

Search: onr:"swepub:oai:DiVA.org:uu-430967" > PD-L1 expression in...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3

Ali, Abir Salwa, 1986- (author)
Uppsala universitet,Onkologisk endokrinologi
Langer, Seppo W. (author)
Federspiel, Birgitte (author)
show more...
Hjortland, Geir Olav (author)
Grønbæk, Henning (author)
Ladekarl, Morten (author)
Welin, Staffan (author)
Uppsala universitet,Onkologisk endokrinologi
Weber Vestermark, Lene (author)
Arola, Johanna (author)
Osterlund, Pia (author)
Knigge, Ulrich (author)
Sørbye, Halfdan (author)
Micke, Patrick (author)
Uppsala universitet,Klinisk och experimentell patologi,Patrick Micke
Grimelius, Lars (author)
Uppsala universitet,Experimentell och klinisk onkologi
Grönberg, Malin, 1980- (author)
Uppsala universitet,Onkologisk endokrinologi
Tiensuu Janson, Eva (author)
Uppsala universitet,Onkologisk endokrinologi
show less...
 (creator_code:org_t)
2020-12-14
2020
English.
In: PLOS ONE. - : Public Library of Science (PLoS). - 1932-6203. ; 15:12
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Gastroenteropancreatic neuroendocrine neoplasms grade 3 (GEP-NENs G3) are rare tumors. These highly aggressive neoplasms are traditionally treated with platinum-based chemotherapy in combination with etoposide. Immune checkpoint proteins such as programmed cell death ligand (PD-L1) may have a role in different cancers allowing them escape the immune system and hence, progress. We aimed to investigate the immunohistochemical expression of PD-L1 in GEP-NEN G3 and evaluate its correlation to clinical parameters. In a cohort of 136 patients, 14 (10%) expressed PD-L1 immunoreactivity; four (3%) patients in the tumor cells and 10 (7%) had immunoreactive immune cells. PD-L1 expression did not correlate to clinical parameters, progression-free survival or overall survival. We conclude that PD-L1 expression is present only in a subset of GEP-NEN G3 patients. Further studies are needed to fully understand the role of PD-L1 in patients with GEP-NEN G3, including the future possibility for treatment with immune checkpoint inhibitors.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

  • PLOS ONE (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view